Lilly Q3 2026 Results: What Changed for Retatrutide

What Did Lilly Report on 29 October 2026?

Eli Lilly published its third-quarter 2026 results on 29 October 2026 in a Form 8-K filing.[1] The headline figures were financial: revenue increased 39% to $24.4 billion, driven primarily by Mounjaro and Zepbound; reported EPS was $7.22 and non-GAAP EPS $7.48, both including $4.57 per share of acquired in-process R&D charges; and the midpoint of full-year 2026 revenue guidance was raised by $5.5 billion to a range of $91.0 to $92.0 billion.[1] Pre-release consensus, per an S&P Global preview, had been roughly $22.5 billion in revenue.[2]

For researchers following the incretin class, the relevant pipeline item was the company’s head-to-head Phase 3 readout of retatrutide against semaglutide 2 mg in adults with type 2 diabetes, announced the day before.[1] We cover that trial separately in our TRANSCEND-T2D-2 topline guide. This article is about what the earnings filing does, and does not, add to the retatrutide evidence picture.

Is Retatrutide Approved, and When Does Lilly Plan to File?

Retatrutide is not approved by the FDA, the MHRA or any other regulator, and Lilly’s own public FAQ continues to describe it as an investigational medication.[3] Lilly has said it plans to submit a biologics licence application to the FDA in the first quarter of 2027, a shift from an earlier 2026 target; Lilly told CNBC it needed more time to compile manufacturing and quality-control data for the agency.[4] If a submission is made on that schedule, regulatory review would follow, and any decision would come after it. For our fuller reading of that timeline see the guide on the filing delay and CMC data.

The practical point for researchers is that a financial filing and a regulatory submission are different things. An earnings release signals the sponsor’s intentions; only an accepted application and a published review establish what a regulator has concluded.

What Evidence Is Still Pending for Retatrutide?

Several items remain open as of 3 November 2026. Lilly has described a programme of further Phase 3 studies across indications, and full datasets from many of them are still to be presented at scientific meetings or published in peer-reviewed journals.[5] The TRANSCEND-T2D-2 readout is itself topline and sponsor-reported; its dose-by-dose tables and safety detail await a full presentation. In our pre-earnings piece we listed the open questions going into the quarter: BLA timing, the Seventh Circuit classification dispute and access arrangements. None of those was resolved by a financial release alone.

Researchers should also keep separate three layers of information that are often blended in headlines: (1) peer-reviewed trial publications, (2) sponsor topline press releases, and (3) financial or investor commentary. Layer three is the least suitable for scientific conclusions. Where secondary outlets, including AI-generated summaries, paraphrase earnings coverage, figures can drift from the primary release, so we cite the filing or the sponsor’s own statement wherever one is available.

What Should Researchers Watch Next?

Four markers will tell the field more than any further financial commentary. First, a full presentation or journal publication of TRANSCEND-T2D-2, including the estimand, randomised sample size and adverse-event tables. Second, confirmation that a US submission has actually been made and accepted for review, which Lilly has placed in the first quarter of 2027. Third, any ruling in the litigation over how the FDA classifies the compound, summarised in our classification lawsuit guide. Fourth, MHRA positions on unlicensed retatrutide products in the UK, where the regulator has already published enforcement activity. Each is a primary-source event that can be dated and cited; we will report them as they occur, with the same separation between licensed pharmaceutical development and laboratory reagents.

How Does the Earnings Context Relate to Early Access and Enforcement?

Two adjacent threads are worth tracking. Lilly confirmed on 3 August 2026 that a defined group of patients could apply for early access to the investigational drug under restricted eligibility, which our expanded access summary covers.[6] Separately, Lilly has pursued legal action against businesses it alleges are illegally marketing retatrutide, and regulators including the MHRA have published warnings about unlicensed products. Neither thread alters the compound’s regulatory status; both are context for why provenance, labelling and documentation matter in laboratory sourcing.

How Does Licensed Pharma Development Differ From Research-Use Compounds?

Lilly’s retatrutide programme is a regulated clinical development: a licensed pharmaceutical sponsor, registered protocols, ethics oversight and medical supervision. Nothing in a corporate earnings report transfers to a laboratory reagent. Velox Peptides supplies retatrutide solely as an HPLC-verified in vitro research reagent, with no therapeutic claims, and we report company and regulatory news only as third-party information for researchers. For specifications see the research-grade retatrutide page.

This compound is supplied as a research reagent only. It is not a medicine and has not been evaluated by the MHRA or FDA. Not for human or veterinary use. See our Research Use Policy and MHRA Statement.

Frequently Asked Questions